[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-periodontitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-periodontitis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,71,104,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100643839","phase-4-clinical-and-radiographic-evaluation-of-doxycycline-and-atorvastatin-loaded-chitosan-nanoparticles-as-an-adjunctive-to-scaling-and-root-planning-in-the-management-of-chronic-periodontitis-a-randomized-controlled-clinical-trial-100643839",false,"NCT07634341","Clinical and Radiographic Evaluation of Doxycycline and Atorvastatin Loaded Chitosan Nanoparticles as an Adjunctive to Scaling and Root Planning in the Management of Chronic Periodontitis. A Randomized Controlled Clinical Trial.","Clinical and Radiographic Evaluation of Doxycycline and Atorvastatin Loaded Chitosan Nanoparticles as an Adjunctive to Scaling and Root Planning in the Management of Chronic Periodontitis: A Randomized Controlled Clinical Trial.","Inclusion Criteria:\n\n* In order for patients to be considered in the study, they must meet the following criteria: 1) they should have stage II and stage III periodontitis 2) Patients' age range equal or more than 25 years old .\n\nExclusion Criteria:\n\n\\- Patients with any systemic condition that may affect periodontal health and bone formation, such as; those who are pregnant, nursing, or postmenopausal women; DM, CVD, metabolic syndrome, osteoporosis, AIDS and chronic alcoholism .\n\n2\\) Patients having local factors that may aggravate and predispose for periodontal diseases such as; orthodontic and prosthetic appliances and parafunctional habits 3)smoking (A patient was classified as a current smoker if they smoked more than 10 cigarettes per day regularly for a minimum period of 5 years) 4) Individuals on systemic drug affecting metabolic bone diseases , Medications taken for the treatment of arthritis and psychotropic and epileptic disorders, as well as anticoagulants, antacids, bisphosphonates, corticosteroids, and antineoplastic drugs, can profoundly affect bone metabolism","ALL","25 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Chronic periodontitis is one of the most prevalent inflammatory diseases affecting the tooth-supporting structures and is characterized by progressive clinical attachment loss and alveolar bone resorption resulting from a complex interaction between pathogenic microorganisms and the host inflammatory and immune responses. If left untreated, the disease may ultimately lead to tooth loss and negatively affect oral health and quality of life.\n\nScaling and root planing (SRP) is considered the gold-standard non-surgical treatment for chronic periodontitis. It aims to remove dental plaque and calculus deposits and reduce the subgingival bacterial load. Although SRP has demonstrated significant clinical benefits, its effectiveness may be limited in certain situations, particularly in deep periodontal pockets and anatomically complex areas that are difficult to access. Therefore, adjunctive therapeutic approaches have been investigated to enhance treatment outcomes and improve long-term periodontal stability.\n\nIn recent years, local drug delivery systems have gained considerable attention in periodontal therapy due to their ability to provide high therapeutic concentrations directly at the site of infection while minimizing systemic adverse effects. Chitosan has emerged as a promising biomaterial for this purpose because of its excellent biocompatibility, biodegradability, antimicrobial properties, and its ability to form nanoparticles capable of sustained and controlled drug release within periodontal pockets.\n\nDoxycycline is widely used in periodontal treatment because of its antimicrobial activity against periodontal pathogens as well as its ability to inhibit matrix metalloproteinases (MMPs), which play a key role in connective tissue destruction and alveolar bone loss. Furthermore, recent studies have demonstrated that atorvastatin, beyond its well-known lipid-lowering effects, possesses anti-inflammatory, immunomodulatory, and osteogenic properties that may contribute to periodontal tissue regeneration and improved clinical outcomes.\n\nThe research problem arises from the limited effectiveness of scaling and root planing alone in some cases of chronic periodontitis and the need for innovative adjunctive therapies that combine antimicrobial, anti-inflammatory, and bone regenerative effects. Therefore, evaluating the therapeutic potential of chitosan nanoparticles loaded with doxycycline and atorvastatin may provide a novel and effective approach for periodontal treatment.\n\nThe aim of this study is to clinically and radiographically evaluate the effectiveness of chitosan nanoparticles loaded with doxycycline and atorvastatin as an adjunct to scaling and root planing in patients with chronic periodontitis. Clinical outcomes, including probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), and bleeding on probing (BOP), as well as radiographic changes in alveolar bone levels, will be assessed and compared with conventional treatment outcomes. The findings of this study may contribute to the development of a more effective and biologically targeted therapeutic strategy for the management of chronic periodontitis.",[26],"Chronic Periodontitis",[28],"deep periodontal pocket local drug Doxycycline Atorvastatin","NOT_YET_RECRUITING","2026-06-03",{"date":32,"type":33},"2026-06-08","ACTUAL",{"date":35,"type":20},"2026-06",{"date":37,"type":20},"2027-12",{"name":39,"class":40},"Fayoum University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":41},"100627746","vector-system-vs-mini-five-curettes-in-non-surgical-periodontal-therapy-100627746","NCT07452640","Vector® System vs Mini-Five Curettes in Non-Surgical Periodontal Therapy","A Randomized Single-Blind Clinical Trial Comparing the Clinical and Radiographic Outcomes of the Vector® Ultrasonic System and Minimally Invasive Hand Instrumentation (Mini-Five Curettes) in Non-Surgical Periodontal Therapy","VECTOR-RCT","Inclusion Criteria:\n\nAdults aged 18-65 years Willing to participate and provided written informed consent Presence of single-rooted teeth in both maxilla and mandible with vertical bone defects (radiographic intrabony defect ≥2 mm and probing depth ≥5 mm) Diagnosis of Stage III or Stage IV periodontitis Systemically healthy or Systemically healthy patients or American Society of Anesthesiologists (ASA) physical status I-II.\n\nExclusion Criteria:\n\nPeriodontal treatment within the last 6 months Teeth with furcation involvement Smoking more than 10 cigarettes per day Pregnancy Age under 18 years Patients unwilling to attend regular follow-up visits Previously endodontically treated tooth at the treatment site Poor compliance with oral hygiene instructions Single-rooted teeth with horizontal bone loss extending close to the apical third Teeth with mobility grade II or III Previous flap surgery or regenerative periodontal treatment at the study site","18 Years","65 Years",{"count":53,"type":20},36,[55],"NA","This randomized clinical trial aims to compare the clinical and radiographic outcomes of the Vector®️ ultrasonic system and mini-five curettes in non-surgical periodontal therapy. Patients diagnosed with periodontitis will be randomly assigned to either ultrasonic instrumentation or manual instrumentation. Clinical periodontal parameters and radiographic bone level changes will be evaluated at baseline, 1, 3, 6, and 12 months. The primary objective is to assess differences in clinical attachment level and probing depth reduction between the two treatment modalities.",[58,26],"Periodontitis",[60],"Non-Surgical Periodontal Therapy • Vector System • Ultrasonic Instrumentation • Mini-Five Curettes • Clinical Attachment Level • Radiographic Bone Loss","RECRUITING","2026-03-01",{"date":64,"type":33},"2026-03-05",{"date":66,"type":33},"2026-02-19",{"date":68,"type":20},"2028-02",{"name":70,"class":40},"Hacettepe University",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100609482","metformin-versus-chlorhexidine-gel-as-adjuncts-to-scaling-and-root-planing-in-stage-ii-grade-b-periodontitis-100609482","NCT07215156","Metformin Versus Chlorhexidine Gel as Adjuncts to Scaling and Root Planing in Stage II Grade B Periodontitis","Comparative Study Between Metformin and Chlorhexidine Gel as Adjunctive to Conventional Non-Surgical Treatment of Stage II Grade B Periodontitis: A Randomized Controlled Clinical Trial","MET-CHX Perio","Inclusion Criteria:\n\nAdults aged 18-60 years.\n\nDiagnosis of Stage II, Grade B periodontitis.\n\nProbing pocket depths ≤ 5 mm with clinical attachment loss of 3-4 mm in selected sites.\n\nGenerally healthy individuals without systemic conditions affecting periodontal health.\n\nExclusion Criteria:\n\nCurrent smokers or users of tobacco products.\n\nPregnant or lactating women.\n\nKnown allergy to metformin or chlorhexidine.\n\nUse of antibiotics or anti-inflammatory drugs within the past 3 months.\n\nHistory of periodontal therapy within the past 6 months.","60 Years",{"count":81,"type":20},60,[55],"This clinical trial is designed to evaluate two locally delivered gels, metformin and chlorhexidine, as adjunctive therapies to scaling and root planing (SRP) in patients with Stage II, Grade B periodontitis. Periodontitis is a chronic inflammatory condition that damages the supporting tissues of the teeth. Although SRP is the standard non-surgical treatment, it may not fully eliminate harmful bacteria or prevent disease recurrence.\n\nChlorhexidine is a widely used antimicrobial gel, while metformin, a medication commonly prescribed for diabetes, has shown anti-inflammatory and bone-supportive effects when used locally in the gums. This study will directly compare the effectiveness of 1% metformin gel and 0.2% chlorhexidine gel, both applied subgingivally after SRP, against SRP alone.\n\nSixty adult participants diagnosed with Stage II, Grade B periodontitis will be randomly assigned into three groups: SRP only (control), SRP plus metformin gel, and SRP plus chlorhexidine gel. Clinical outcomes (plaque index, gingival index, probing pocket depth, and clinical attachment level), inflammatory markers (MMP-8 in gingival crevicular fluid), and radiographic bone density will be measured at baseline, 1 month, 3 months, and 6 months.\n\nThe goal is to determine whether metformin gel or chlorhexidine gel provides superior improvements in periodontal healing when compared with SRP alone. Findings from this trial may guide evidence-based decisions on optimizing non-surgical periodontal therapy.",[85,26],"Stage II, Grade B Periodontitis",[58,87,26,88,89,90,91,92,93,94],"Stage II Grade B Periodontitis","Scaling and Root Planing (SRP)","Non-surgical Periodontal Therapy","Metformin Gel","Chlorhexidine Gel","Local Drug Delivery","Periodontal Regeneration","Inflammatory Markers (MMP-8)","2025-10-02",{"date":97,"type":33},"2025-10-10",{"date":99,"type":20},"2025-10-06",{"date":101,"type":20},"2026-06-01",{"name":103,"class":40},"Kafrelsheikh University",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":112,"sex":16,"minAge":50,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":41},"100272983","b-cell-functions-in-periodontitis-100272983","NCT02833285","B Cell Functions in Periodontitis","Periodontitis and Inflammation : Biological and Clinical Approach of B Cell Role.","LBPARO","Inclusion Criteria:\n\n* Requiring periodontal surgery\n* In good health\n* Having signed consent\n\nExclusion Criteria:\n\n* Minor\n* Patient having taken antibiotics in the previous 3 months\n* Patients with systemic diseases including chronic inflammatory disease\n* Pregnancy\n* orthodontic treatment ongoing",true,"75 Years",{"count":81,"type":20},"OBSERVATIONAL","The inflammatory response involves many players from the immune response, including B lymphocytes. These cells are responsible for the synthesis of immunoglobulins in response to the presence of an antigen. They are characteristic of chronic inflammation. There are several subsets of B cells characterized by specific membrane markers. Once activated, these cells express many factors contributing to tissue destruction seen in periodontitis and particularly in osteoclastogenesis (receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor, interleukin-6, macrophage inflammatory protein-1α and Monocyte Chemoattractant Protein-3).\n\nDuring the establishment of a periodontal disease, an important inflammatory infiltrate is observed in the gum. This infiltrate is characterized by the presence of many B lymphocytes. B cell subsets in the blood and the gum of patients with periodontitis have been little studied. However, the number of autoreactive B cells (cluster of differentiation (CD)19+, CD5+) has been reported to be higher in the blood of patients with periodontal disease. In the gum, the rate of B and T cells increases with the level of inflammation and is correlated with the severity of the inflammatory process. Activation of B cells is a prerequisite for the progression of gingivitis to periodontitis. B cell distribution could then be an indicator of disease progression, but also allow to study the response to treatment.\n\nThe aim of this pilot study is to characterize B cell subsets in the blood and the gum of patients with periodontitis, according to disease activity. Analysis of B cells in the blood could highlight the association of a particular subpopulation with aggressive periodontal disease and evidence a particular biological profile of the host response. The investigators also wish to observe the evolution of this phenotype following an unconventional surgical therapy.\n\nThis study would better understand the pathogenesis of periodontal disease and refine the diagnosis, prognosis and treatment of periodontitis, and thus participate in the development of personalized medicine. Biological monitoring of therapeutic effects may be initiated and allow more effectively prevent recurrence.",[26,118],"Aggressive Periodontitis","2025-09-16",{"date":121,"type":33},"2025-09-17",{"date":123,"type":33},"2015-05-01",{"date":125,"type":20},"2025-09",{"name":127,"class":40},"University Hospital, Brest",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":41},"100366126","the-link-between-periodontitis-smoking-and-oral-cancer-100366126","NCT04047212","The Link Between Periodontitis, Smoking and Oral Cancer","Analysis of the Link Between Periodontitis, Smoking and Oral Cancer: Cohort Study","Inclusion Criteria:\n\n* Patients 18 years or older.\n\nExclusion Criteria:\n\n* Patients with any systemic diseases.\n* Pregnant females.\n* Handicapped and mentally retarded patients.\n* Patients undergoing radiotherapy.\n* Patients having oral cancer",{"count":136,"type":20},200,"Periodontitis is a widely prevalent disease worldwide that has serious public health consequences. Its prognosis includes tooth loss and edentulism, a condition that negatively affects chewing causing functional disability; and esthetics causing social impairment. Consequently, periodontitis may end up causing marked impairment of the quality of life of the affected patients, impairment of general health and increasing the dental care costs significantly.\n\nChanges in the oral mucosa arise by primary products resulting from tissue breakdown due to gingivitis. It then triggers the host cells to produce proteinases that mediate loss of marginal periodontal ligaments, apical migration of the junctional epithelium and apical spread of bacterial biofilm.\n\nTherefore, this research aims to identify the risk of smoking to both periodontitis and oral cancer, and the risk of periodontitis to oral cancer.",[26,139],"Oral Cancer","2021-06-13",{"date":142,"type":33},"2021-06-16",{"date":144,"type":20},"2021-08-12",{"date":146,"type":20},"2032-01-30",{"name":148,"class":40},"Cairo University"]